Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis

Abstract Engraftment syndrome (ES), a complication of autologous hematopoietic cell transplantation (auto-HCT), can occur around the time of neutrophil recovery. We sought to identify the incidence of ES in light chain (AL) amyloidosis patients undergoing auto-HCT at our centre by evaluating 72 consecutive amyloidosis patients transplanted between 1999 and 2017. To assess trends in ES over time, patients were divided into two Eras (Era 1 = 1999–2008 and Era 2 = 2009–2017) based on year of auto-HCT. Twenty-two (31%) patients developed ES; three (16%) and 19 (36%) in Era 1 and 2, respectively (p = .1). Three (16%) and 51 (96%) patients in Era 1 and 2 received chemotherapy before auto-HCT (p =  <.001). The most common symptoms observed with ES in addition to fever was diarrhoea (73%), rash (68%), weight gain (56%) and non-cardiogenic pulmonary oedema (23%). Day 100 post-auto-HCT haematological response (19.5% vs. 14%, p = .7) or post-transplant best organ response (23% vs. 36%, p = .2) were not significantly different in patients who did not or did develop ES, respectively. In this single centre series, we define the incidence and characteristics of ES in AL amyloidosis patients undergoing auto-HCT.

[1]  G. Gutiérrez-García,et al.  Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation , 2018, Bone Marrow Transplantation.

[2]  P. Hari,et al.  Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  W. Wood,et al.  Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Hari,et al.  Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation , 2015, Bone Marrow Transplantation.

[5]  J. Ritz,et al.  Current issues in chronic graft-versus-host disease. , 2014, Blood.

[6]  P. Hari,et al.  Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  D. Dingli,et al.  Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  R. Falk,et al.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis , 2012, Leukemia.

[9]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Costa,et al.  Post-autologous hematopoietic SCT engraftment syndrome:a single center experience , 2012, Bone Marrow Transplantation.

[12]  D. Dingli,et al.  Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light‐chain amyloidosis , 2012, American journal of hematology.

[13]  S. Trudel,et al.  Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation , 2011, American journal of hematology.

[14]  D. Hurd,et al.  Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. , 2010, Clinical lymphoma, myeloma & leukemia.

[15]  M. Lozano,et al.  Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center , 2010, Bone Marrow Transplantation.

[16]  A. Dalgleish,et al.  The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells , 2009, Cancer Immunology, Immunotherapy.

[17]  K. Tarte,et al.  Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor1 , 2006, The Journal of Immunology.

[18]  S. Fernandez,et al.  Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome , 2004, Bone Marrow Transplantation.

[19]  Â. Maiolino,et al.  Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria , 2003, Bone Marrow Transplantation.

[20]  B. Pollock,et al.  Engraftment syndrome in breast cancer patients after stem cell transplantation is associated with poor long-term survival. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  T. Spitzer.  Engraftment syndrome following hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.

[22]  G. Goodwin,et al.  An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose , 2000, Bone Marrow Transplantation.

[23]  R. Kyle,et al.  Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL) , 2000, Bone Marrow Transplantation.

[24]  P. Kubilis,et al.  Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients , 1997, Bone Marrow Transplantation.

[25]  A. Delannoy,et al.  Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. , 1996, Bone marrow transplantation.

[26]  R. Gingrich,et al.  Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. , 1995, Bone marrow transplantation.

[27]  M. Mihm,et al.  ACUTE GRAFT-VERSUS-HOST DISEASE IN RECIPIENTS OF BONE-MARROW TRANSPLANTS FROM IDENTICAL TWIN DONORS , 1979, The Lancet.